Malignant pleural mesothelioma
MONDO:0005112A malignant neoplasm that arises from mesothelial cells in the pleura and shows a diffuse growth pattern. It arises on the parietal and sometimes visceral pleura as multiple small nodules that later become confluent and invade the chest wall adipose tissue and muscle. Asbestos exposure is the main cause for the development of pleural malignant mesothelioma. It usually affects patients over sixty years of age. The latency period is long. Patients usually present with pleural effusion, dyspnea and chest wall pain. Additional signs and symptoms include chills, sweating, weight loss, and weakness. Morphologic variants include epithelioid, desmoplastic, sarcomatoid, and biphasic mesothelioma. The clinical course is usually aggressive.
Also known as: pleura mesothelioma, malignant mesothelioma of pleura, malignant mesothelioma of the pleura, malignant pleural mesothelioma, pleural diffuse malignant mesothelioma, pleural malignant mesothelioma
2832 clinical trials for this condition and its sub-types, 71 tagged with Malignant pleural mesothelioma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Malignant pleural mesothelioma
-
Pleural epithelioid mesothelioma 8 trials
-
Pleural sarcomatoid mesothelioma 2 trials
-
Immunotherapy combo studied for rare lung cancer, trial stopped early
Disease control Stopped earlyThis study tested two immunotherapy drugs, durvalumab and tremelimumab, in people with malignant pleural mesothelioma, a rare cancer of the lung lining. The trial enrolled 19 participants whose cancer had worsened after standard chemotherapy. The goal was to see if the drug combi…
Phase 2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Mesothelioma radiation trial ends early – few answers found
Disease control Stopped earlyThis study looked at whether adding targeted radiation therapy to surgery and chemotherapy could help people with early-stage pleural mesothelioma live longer. Only 16 people took part before the trial was stopped early, so we don't have clear results. The approach aimed to kill …
Phase 3 • Sponsor: NRG Oncology • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
Engineered immune cells take aim at Mesothelin-Positive tumors
Disease control Stopped earlyThis trial tests a new cell therapy called TC-510 for people with advanced cancers that have a protein called mesothelin on their surface, including mesothelioma, ovarian cancer, and pancreatic cancer. TC-510 uses a patient's own immune cells, which are genetically modified to be…
Phase 1/2 • Sponsor: TCR2 Therapeutics • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
Light therapy boosts immune attack on lung cancer? early trial halted
Disease control Stopped earlyThis early-phase trial tested whether a light-activated drug (photodynamic therapy) could help immunotherapy work better in patients with non-small cell lung cancer that has spread to the lining of the lung or with mesothelioma. Only 5 people took part, and the study was stopped …
Phase 1 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
Experimental combo for rare lung cancer shows early promise but trial halted
Disease control Stopped earlyThis early-phase trial tested the drug pembrolizumab (Keytruda) combined with targeted radiation (SBRT) in 5 people with advanced malignant pleural mesothelioma, a rare cancer of the lung lining. The goal was to check safety and find the right dose. The study was terminated early…
Phase 1 • Sponsor: Royal Marsden NHS Foundation Trust • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
Experimental lung cancer combo trial ends early
Disease control Stopped earlyThis phase 2 trial tested a new drug called THOR-707 (Pegenzileukin) combined with other cancer treatments, including pembrolizumab, in 106 people with advanced lung cancer or pleural mesothelioma. The goal was to see if the combination could shrink tumors. However, the study was…
Phase 2 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
Mesothelioma drug trial halted early – what we know
Disease control Stopped earlyThis phase 2 trial tested whether the drug nintedanib could help people with malignant pleural mesothelioma keep their cancer from growing after initial chemotherapy. 37 patients were randomly assigned to receive either nintedanib or a placebo twice daily. The study was terminate…
Phase 2 • Sponsor: European Organisation for Research and Treatment of Cancer - EORTC • Aim: Disease control
Last updated Jun 26, 2026 18:48 UTC